Antibody-drug Conjugates (ADC)

N3-TEMPO is an azide-containing click chemistry reagent that serves as a powerful tool for bioorthogonal reactions. It is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-bearing compounds, facilitating the conjugation of nucleic acids, lipids, and proteins. Additionally, N3-TEMPO can participate in ring strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO or BCN moieties. Its high yield, specificity, and operational simplicity make it valuable for various applications in chemical biology and bioconjugation research.

Boc-C14-COOH is a non-cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing therapeutic efficacy while maintaining target specificity. Additionally, Boc-C14-COOH serves as an alkyl chain-based PROTAC linker, enabling the development of proteolysis-targeting chimeras for targeted protein degradation studies. Its applications extend to various fields, including cancer research and drug development.

Fmoc-Gly-Gly-OH is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the attachment of drugs to antibodies, enhancing targeted delivery and efficacy in tumor cells. Its use in research supports the development of novel therapeutic strategies in oncology, allowing for improved specificity and reduced systemic toxicity in cancer treatment approaches.

Bis-PEG13-NHS ester is a polyethylene glycol (PEG) based linker primarily utilized in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This compound features a cleavable NHS ester that facilitates effective conjugation to target molecules, enhancing the delivery of therapeutic agents. Its application in constructing PROTACs allows for targeted protein degradation, making it a powerful tool in drug development and cancer research.

Fmoc-NH-PEG6-CH2COOH is a cleavable linker that targets PROTAC applications, facilitating the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This PEG-based compound enhances the solubility and bioavailability of therapeutic agents. Its unique structure allows for selective cleavage, making it suitable for drug development and targeted protein degradation studies in various research settings.

Mal-amide-PEG8-Val-Ala-PAB-PNP is a cleavable linker specifically designed for antibody-drug conjugate (ADC) synthesis. This compound facilitates targeted drug delivery by allowing the selective release of therapeutic agents upon internalization in cancer cells. Its application in ADC development enhances therapeutic efficacy while minimizing off-target effects, making it a valuable tool for researchers in cancer treatment studies.

Azido-C6-OH is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This compound features an azide group and is suitable for click chemistry applications, as it can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, Azido-C6-OH can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with compounds that carry DBCO or BCN groups, making it a versatile tool for conjugation in chemical biology research.

Bis-PEG21-NHS ester is a polyethylene glycol (PEG) based linker with a primary mechanism as a cleavable ADC and PROTAC linker. This compound facilitates the synthesis of PROTACs and antibody-drug conjugates (ADCs) by providing a stable yet versatile connecting moiety. Its unique properties support targeted drug delivery and enhance the specificity of therapeutic applications in chemical biology research.

Boc-NH-PEG6-CH2CH2COOH is a cleavable linker primarily utilized in antibody-drug conjugates (ADCs). This PEG-based compound facilitates effective drug delivery by conjugating therapeutic agents to antibodies, enhancing target specificity and reducing off-target effects. Additionally, Boc-NH-PEG6-CH2CH2COOH can serve as a linker in the synthesis of PROTACs, contributing to the development of targeted protein degradation strategies in chemical research.

m-PEG8-Amine is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing systemic toxicity. Its application in ADC development supports advancements in targeted cancer therapies and drug delivery systems.

Boc-NH-PEG1-CH2CH2COOH is a cleavable ADC linker featuring a polyethylene glycol (PEG) moiety. This reagent facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling the release of the drug payload upon cellular internalization. In addition, it can serve as a linker for alkyl/ether-based PROTACs, promoting targeted protein degradation in research applications.

Amino-PEG3-C2-acid is a cleavable polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent enhances the therapeutic efficacy of ADCs by facilitating the selective release of cytotoxic agents within target cells. Additionally, Amino-PEG3-C2-acid serves as a PEG-based linker in the development of PROTACs, enabling targeted protein degradation for advanced research applications in drug discovery and development.

Biotin-PEG1-NH2 is a cleavable linker featuring a one-unit polyethylene glycol (PEG) structure, specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of biotin to antibodies, enhancing stability and efficacy in targeted drug delivery. Its applications extend to cancer research where ADCs are utilized for selective targeting and therapy, providing a mechanism to improve therapeutic index and reduce off-target effects.

(R)-Azetidine-2-carboxylic acid is a non-cleavable linker specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound effectively facilitates the stable attachment of therapeutic agents to antibodies, enhancing targeted delivery to cancer cells. Additionally, (R)-Azetidine-2-carboxylic acid serves as an alkyl chain-based PROTAC linker, providing versatility in the development of proteolysis-targeting chimera applications.

Fmoc-Ala-Ala-PAB is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the efficient delivery of cytotoxic agents to target cells, enhancing therapeutic efficacy while minimizing off-target effects. Its properties make it a valuable tool in the development and optimization of ADCs for cancer research and treatment applications.

Azide-PEG3-Tos is a PEG-based PROTAC linker that facilitates the synthesis of proteolysis-targeting chimeras (PROTACs). This non-cleavable linker consists of a three-unit polyethylene glycol (PEG) structure, making it suitable for the development of antibody-drug conjugates (ADCs). Azide-PEG3-Tos acts as a click chemistry reagent, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. Its versatile reactivity and stability make it a valuable tool in chemical biology research and drug development.

Aminooxy-PEG2-azide is a PEG-based PROTAC linker that facilitates the synthesis of protein degraders. This non-cleavable 2-unit PEG linker is also utilized in the preparation of antibody-drug conjugates (ADCs). As a versatile click chemistry reagent, it features an azide group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. Its applications are essential in advancing targeted protein degradation and ADC development.

20-(tert-Butoxy)-20-oxoicosanoic acid is a non-cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). This compound plays a crucial role in enhancing the stability and efficacy of ADCs by facilitating site-specific drug delivery. Additionally, it serves as an alkyl chain-based linker in the development of PROTACs, which are designed to induce targeted protein degradation. Its versatile applications make it a valuable tool in chemical biology and therapeutic research.

Bis-sulfone-PEG3-Azide is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAC) as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules. Its versatility makes it a valuable tool in research applications focused on protein degradation and targeted delivery of therapeutic agents.

CL2A is a cleavable linker designed for antibody-drug conjugates (ADCs), incorporating PEG8 and a triazole structure within a PABC-peptide framework. This linker exhibits pH sensitivity, facilitating a bystander effect upon cleavage and forming a disulfide bond with cysteine residues on antibodies. CL2A is suitable for research applications focused on optimizing ADC formulations and enhancing therapeutic efficacy through targeted delivery mechanisms.

m-PEG8-NHS ester is a non-cleavable 8 unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Its primary mechanism involves forming stable amide bonds with antibody proteins via its N-hydroxysuccinimide (NHS) functionality. This reagent facilitates the conjugation of therapeutic agents to antibodies, enhancing the efficacy and specificity of targeted drug delivery in various cancer research applications.

Azetidin-3-ol hydrochloride is a non-cleavable linker for antibody-drug conjugates (ADCs) that facilitates the effective delivery of cytotoxic agents to targeted cells. This compound also serves as an alkyl chain-based PROTAC linker, enabling the synthesis of proteolysis-targeting chimeras for targeted protein degradation studies. Its applications extend to enhancing therapeutic efficacy in cancer research and other disease models.

Mal-PEG2-acid is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs), facilitating the stable attachment of cytotoxic agents to antibodies. This reagent can be conjugated to Tubulysin and its derivatives, enabling targeted delivery of therapeutic compounds. Additionally, Mal-PEG2-acid serves as a linker in PROTAC synthesis, aiding in the development of innovative targeted protein degradation strategies.

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a cleavable PEG linker designed for use in antibody-drug conjugates (ADCs) and PROTACs. Its unique structure facilitates the stable attachment of drugs to antibodies while preserving the ability to release the active compound upon internalization. This reagent is essential for researchers developing targeted therapies, enabling more efficient delivery and controlled release of therapeutic agents. Its versatility as both an ADC linker and PROTAC linker supports advancements in drug design and development workflows.

MC-Val-Ala-OH is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the precise release of therapeutic agents in a controlled manner upon internalization by target cells. This compound plays a crucial role in enhancing the efficacy of ADCs by ensuring targeted delivery and minimizing off-target effects, making it an essential reagent in cancer research and therapeutic development.

Amino-PEG8-Boc is a cleavable eight-unit polyethylene glycol (PEG) linker utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates improved stability and solubility in ADC formulations. Additionally, Amino-PEG8-Boc serves as a PEG-based linker for the development of protein-targeting chimeras (PROTACs), allowing for innovative therapeutic applications in targeted protein degradation studies.

m-PEG4-Amine is a PEG-based linker primarily utilized in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This compound features a cleavable link, enabling the targeted delivery of therapeutic agents while providing controlled release upon cellular internalization. Its application is pivotal in advancing research in targeted protein degradation and therapeutic modalities, enhancing drug efficacy and specificity in various biological systems.

Azide-C2-SS-C2-biotin is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). Featuring an azide functionality, it facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules and supports strain-promoted alkyne-azide cycloaddition (SPAAC) when interacting with DBCO or BCN groups. This reagent is essential for the development of targeted therapeutic strategies in bioconjugation research and ADC formulation.

NH2-PEG8-acid is a non-cleavable linker composed of an 8-unit polyethylene glycol (PEG) chain, which is utilized in the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of therapeutic agents to antibodies, enhancing the delivery and efficacy of targeted therapies. Additionally, NH2-PEG8-acid serves as a PEG-based linker in the development of PROTACs (proteolysis-targeting chimeras), allowing for precise modulation of protein degradation pathways in research applications.

DBCO-Sulfo-Link-biotin is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It features a DBCO moiety that enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing compounds. This reagent is valuable in the development of targeted therapies, facilitating precise delivery of cytotoxic agents to tumor cells while minimizing off-target effects. Its application enhances the effectiveness of therapeutic strategies in oncology and related fields.

Propargyl-PEG4-NHS ester is a stable, non-cleavable linker designed for antibody-drug conjugates (ADCs) through its ability to facilitate click chemistry reactions. This reagent features an alkyne group, allowing it to engage in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Its streamlined conjugation capabilities make it valuable for the development of targeted therapies and bioconjugation applications in chemical biology and pharmaceuticals.

endo-BCN-PEG4-acid is a versatile cleavable linker designed for antibody-drug conjugates (ADCs), facilitating targeted drug delivery. Featuring a bicyclo[6.1.0]nonyne (BCN) moiety, this compound enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. It is particularly useful in bioconjugation and drug development applications, allowing for the precise attachment of therapeutic agents to antibodies.

4-Azidobenzyl alcohol is an azide compound primarily utilized in click chemistry applications. It features an azide group that can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, enabling the formation of stable triazole linkages. Additionally, this reagent can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups, making it valuable for bioconjugation and surface modification studies in chemical biology.

Propargyl-C1-NHS ester is a non-cleavable linker specifically designed for antibody-drug conjugation (ADC). This reagent features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its applications are significant in bioconjugation techniques, enhancing the precision of targeted therapeutics in chemical biology research.

Fmoc-azetidine-3-carboxylic acid is a cleavable linker specifically designed for antibody-drug conjugate (ADC) synthesis. It serves as an effective alkyl chain-based PROTAC linker for the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted drug delivery and enhances the therapeutic efficacy of conjugates, making it a valuable tool for chemical biology and drug discovery research. Its distinct characteristics allow for precise modifications, thereby supporting innovative applications in ADC and PROTAC design.

H-Glu-OtBu is a non-cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates stable attachment between antibodies and drug moieties, enhancing the efficacy and targeting of ADCs in therapeutic applications. Additionally, H-Glu-OtBu serves as an alkyl chain-based linker in the development of PROTACs, enabling the targeted degradation of proteins. Its versatile functionality makes it an essential reagent in chemical research and drug development.

MC-VC-PAB-NH2 TFA is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the conjugation of cytotoxic agents to antibodies, allowing for targeted delivery of therapeutics. This compound plays a critical role in enhancing the efficacy of ADCs by ensuring selective release of the drug in the tumor microenvironment. Its utilization is pivotal in the development of advanced cancer therapies.

m-PEG7-CH2CH2COOH is a PEG-based PROTAC linker designed to facilitate the synthesis of targeted protein degraders. It serves as a non-cleavable linker in the development of antibody-drug conjugates (ADCs), enhancing the delivery of therapeutic agents. This compound is crucial for researchers working on PROTAC technology and ADC chemistry, enabling better modulation of protein levels in various biological systems. Its unique structure supports effective conjugation and stability for experimental applications in drug development.

Fmoc-Gly-NH-CH2-O-CH2COOH is an ADC linker designed for use in antibody-drug conjugate synthesis. This compound features a glycine residue that facilitates the covalent attachment of cytotoxic drugs to monoclonal antibodies, enabling targeted delivery to tumor cells. Its structural properties enhance the stability and efficacy of the resulting ADCs in therapeutic applications.

Propargyl-PEG2-acid is a non-cleavable linker targeting the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This PEG-based compound facilitates the conjugation process through click chemistry, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. It serves as a vital tool for researchers in the development of innovative therapeutic strategies involving ADCs and targeted protein degradation applications.

N-Boc-PEG5-bromide is a PEG-based linker designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras) and antibody-drug conjugates (ADCs). This cleavable linker facilitates the efficient conjugation of therapeutic agents to antibodies, enabling targeted delivery and enhanced therapeutic efficacy. Its application extends to various research areas in bioconjugation and drug development, making it a valuable tool for advancing therapeutic strategies in cancer and other diseases.

m-PEG4-Br is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs) for enhanced therapeutic efficacy. By distally connecting to the monomethyl auristatin E (MMAE) payload, m-PEG4-Br modulates hydrophilicity, antigen binding, and in vitro potency of the ADC. Additionally, this versatile compound serves as a PROTAC linker, facilitating the development of PROTACs for targeted protein degradation studies.

Mal-VC-PAB-PNP is a cleavable ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to target cells, enhancing therapeutic efficacy while minimizing off-target effects. Its versatile application in ADC development makes it a valuable reagent in cancer research and drug delivery systems.

Ald-Ph-NHS ester is a non-cleavable linker targeting antibody-drug conjugation (ADC) applications. This compound facilitates the stable conjugation of antibodies to cytotoxic agents, enhancing the therapeutic efficacy of ADCs. Its robust linkage ensures effective delivery of pharmacological agents to targeted cells, thereby supporting research in targeted cancer therapies and bioconjugation methodologies.

Boc-Val-Cit-PAB is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of payloads in targeted cancer therapies, enhancing the efficacy of the conjugate while minimizing off-target effects. Its utility in ADC development allows for the precise delivery of cytotoxic agents to cancer cells, promoting advancements in personalized treatment strategies.

Hydroxy-PEG4-(CH2)2-Boc is an uncleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs), facilitating stable conjugation between antibodies and therapeutic agents. Its structure supports efficient delivery of cytotoxic drugs specifically to target cells, enhancing therapeutic efficacy while minimizing off-target effects. Additionally, Hydroxy-PEG4-(CH2)2-Boc serves as a PROTAC linker, making it suitable for the development of proteolysis-targeting chimeras that promote the targeted degradation of specific proteins in various research applications.

1-Boc-azetidine-3-carboxylic acid is a non-cleavable linker targeting antibody-drug conjugates (ADCs) and is utilized in the synthesis of ADCs. This compound also serves as an alkyl chain-based linker for the development of proteolysis-targeting chimeras (PROTACs). Its robust structural features make it suitable for enhancing the efficacy and stability of conjugated drugs in various biopharmaceutical research applications.

Fmoc-Asp-NH2 is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of therapeutic agents to antibodies, enhancing the selectivity and potency of ADCs. Fmoc-Asp-NH2 is critical for optimizing drug delivery and improving therapeutic efficacy in targeted cancer therapies. Its use in research supports the development of innovative treatments by enabling the precise delivery of cytotoxic agents to malignancies.

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione-cleavable linker primarily used in antibody-drug conjugates (ADCs). This compound facilitates the covalent attachment of monoclonal antibodies to cytotoxic agents, enabling selective delivery and targeted therapy. Its unique design enhances the stability of ADCs in circulation while allowing for effective release within targeted tumor environments, making it a valuable tool in cancer research and therapeutic applications.

Bis-PEG25-NHS ester is a PEG-based linker designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras) and antibody-drug conjugates (ADCs). Featuring a cleavable NHS ester moiety, this compound enables precise conjugation and release of biomolecules, facilitating targeted therapeutic strategies. Its versatility makes it suitable for a variety of applications in chemical biology and drug development, particularly in enhancing the selectivity and efficacy of therapeutic agents.